Apollo Health Ventures

Our portfolio company, Ochre Bio, has been listed as one of “20 startups to watch” in 2024 by Sifted, an online magazine backed by The Financial Times, for its AI-driven drug discovery in liver disease: https://lnkd.in/eimQzZ8X A new €100 M healthcare fund is emerging in Europe, signaling strong momentum in longevity-focused investments: Read more about it in the Longevity.Technology article: https://lnkd.in/es2smwbJ A collaborative effort at ETH Zürich has published a new cell atlas of human neural organoids, enabling researchers to replicate brain development better and explore neurological diseases: https://lnkd.in/dSKA88P8 #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

We are thrilled to announce that our portfolio company, Refoxy Pharma, has successfully raised €9.1 M in a seed-extension financing round. This investment, led by Boehringer Ingelheim Venture Fund with participation from Apollo Health Ventures, NRW.BANK Venture, and HTGF | High-Tech Gründerfonds, will accelerate the preclinical development of Refoxy’s novel FOXO3 activators targeting idiopathic pulmonary fibrosis (IPF). IPF is a chronic, age-related lung disease that affects approximately three million people worldwide with limited treatment options. Refoxy’s innovative approach focuses on modulating the FOXO3 transcription factor, a gene associated with longevity, to combat disease progression. For more details, read the full press release: https://lnkd.in/dTaXtFSg #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Meet our COO, Dr. Anela Vukoja, at the BioFIT Event in Lille, France, from December 3rd to 4th. This event is a platform for connecting innovators, investors, and industry leaders in biotech. Anela will also be judging pitch sessions, bringing her expertise to evaluate biotech projects and support the next generation of healthcare innovation. She will also be participating on the panel “Biotech investors’ forecast: Where will early-stage investment go in 2025?” – alongside Florian Denis (Elaia), Oliver Boucher (Zoetis), Frank Hensel (HTGF | High-Tech Gründerfonds), and Philippe Monteyne ( Aliath Bioventures). Reach out if you are in town or let us know via email: info@apollo.vc #BioFIT2024 #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Our portfolio company HAYA Therapeutics recently joined ‘The Bio Report’ podcast to explore the ‘dark genome.’ Samir Ounzain shares how HAYA is harnessing the therapeutic potential of long non-coding RNAs, previously thought to be ‘junk DNA’, to address challenging diseases. Listen in to hear more about their partnership with Eli Lilly and Company and its mission to transform treatments for obesity and metabolic conditions: https://lnkd.in/ghg8Y3kq Jan Adams, Partner at Apollo Health Ventures, was featured in Gründerszene, one of Germany’s leading magazines for the startup and digital economy. As biotech continues to thrive as one of Europe’s most highly financed sectors in 2024, he spotlights “Rising Stars” in biotech: https://lnkd.in/efnwpdvc Promising findings from a recent study published in Wiley’s Aging Cell magazine reveal that E5 treatment significantly enhances healthspan, demonstrating its potential to mitigate age-related decline, improving overall vitality and resilience in older animals: https://lnkd.in/ecpdZDGT #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Pascale Eede, PhD, Associate at Apollo Health Ventures, will be joining a panel at Investival Showcase to discuss “Fueling Innovation: Insights from Investors on Current Biotech VC Funding.” Together with Nate Chang (Playground Global), Thomas Goodman (Cooley LLP), and Vanela Bushi (H Tree Capital), she will dive into:                  •                Key criteria for investment in biotech ventures                  •                Navigating trends and challenges in today’s VC landscape                  •                Positioning biotech companies for funding success This discussion promises valuable perspectives for biotech innovators looking to engage with investors and shape the future of healthcare. We’re excited to be part of a dialogue that encourages growth and investment in transformative biotech solutions. Catch this session on November 18th and connect with Pascale if you’re attending Investival! #Investival #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Meet us at the Jefferies London Healthcare Conference 2024 from November 19th – 21st, where our partners, Dr. Marianne Mertens and Jan Adams, Ph.D., will join global leaders in healthcare, biotech, and investment. With a focus on impactful innovations in health and longevity, we look forward to connecting with pioneers and partners shaping the future of healthcare at one of Europe’s largest healthcare investment events. Reach out if you are in town or let us know via email: info@apollo.vc #JefferiesHealthcare #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Our Associate, Pascale Eede, PhD, will be attending the Investival Showcase in London on November 18th. Organized by LSX - partnering for Life Science eXecutives, the Investival Showcase is renowned for connecting life science and healthcare companies with global investors and industry leaders. With dedicated tracks for Biotech, Medtech, and Digital Health, this event brings together the best of the life sciences sector for networking, strategic masterclasses, and investment opportunities. If you’re in town, be sure to connect with Pascale or let us know via email: info@apollo.vc #Investival #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

Exciting spotlight on our portfolio company Ochre Bio being featured on BBC’s Click. Lara Lewington visited their UK labs to have a look at their groundbreaking work in liver disease treatments using AI-driven drug discovery and innovative testing on non-transplantable human livers: https://lnkd.in/erU4xxUT The potential of the dark genome is enormous, with a recent analysis by PreScouter, Inc. predicting a market worth nearly $300 billion by 2033. Major players like Eli Lilly and Company and Bayer are heavily investing in this research to unlock new therapies for complex diseases, with our portfolio company, HAYA Therapeutics, leading advancements in this space: https://lnkd.in/dSXsaJPQ A recent study, led by researchers from The Jackson Laboratory, found that individual genetic factors may shape how effective caloric restriction is for extending lifespan in mice. This discovery could lead to tailored dietary strategies for longevity: https://lnkd.in/eC5Fi5k6 #ICYDK #ApolloVC #Lifespan #Healthspan #Longevity #VentureCapital

Meet us in Stockholm at the Bio Europe from November 4th – 6th. Our COO, Dr. Anela Vukoja, will attend the industry's largest gathering of biopharma professionals in Europe, organized by the EBD Group. Reach out if you are in town or let us know via email: info@apollo.vc #BIOEurope #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital

We are excited to share that Alexandra Sharon Bause, Co-Founder and Venture Partner at Apollo Health Ventures, recently took the stage at the Milken Institute Asia Summit in Singapore. In the panel, “From Lifespan to Healthspan: The New Frontier of Investment,” Alexandra joined global leaders to discuss how advancements in longevity science and healthspan investment are set to transform lives. She highlighted Apollo’s commitment to leveraging breakthrough discoveries in aging biology to develop therapies that improve both lifespan and healthspan, ensuring healthier, longer lives. A huge thanks to the panelists and moderator Diane Ty for the engaging discussion! You can now catch the full conversation here: https://lnkd.in/edxxMjz2 #MIGlobal #ApolloVC #Healthspan #Longevity #LifescienceVC #VentureCapital